株式会社極東書店トップ商品一覧Identification of Biomarkers, New Treatments, and Vaccines for COVID-19. 1st ed. 2021

商品詳細

Identification of Biomarkers, New Treatments, and Vaccines for COVID-19. 1st ed. 2021

Identification of Biomarkers, New Treatments, and Vaccines for COVID-19. 1st ed. 2021

・ISBN 978-3-030-71696-7 hard EUR 229.99

¥61,475.- (税込) (※)価格はご注文時の参考価格となります。
納品価格につきましては書籍の入荷時点で確定となります。
版元の原価改定、外国為替の変動等により異なる場合がございますので、予めご了承下さい。

お気に入り
著者・編者Guest, Paul C. (ed.),
シリーズ (Advances in Experimental Medicine and Biology)
出版社 (Springer Nature Switzerland AG, SZ)
出版年月2021
ページ数234 pp.
言語ENG
ニュース番号<A01-92654>

解説

The novel coronavirus 2019 (COVID-19) has caused a serious global pandemic in just one year. Nearly every country and territory in the world has been affected by the virus. The virulence and infection rate of the virus are profound, and has required extreme social distancing measures across the globe in order to prevent overwhelming the healthcare services and hospitals. COVID-19 appears to have the greatest effects on elderly individuals and those who have co-morbid diseases, such as diabetes and obesity. As the cases and death rate remain high, there are justified fears of this virus remaining for several months or years to come. To address this, a rapid and unprecedented worldwide mobilization effort has begun to identify effective treatments and develop vaccines. As these begin to be deployed and administered across the globe, many now feel the virus will be brought under control and lives will eventually return to normal.

This new volume will increase readers'understanding of the ongoing COVID-19 pandemic through a series of chapters that address these concerns. Leading experts will discuss new treatment approaches, vaccine development, mental health aspects of the pandemic, and convey the results of survey studies. The book will be an excellent resource for researchers studying virology, metabolic diseases, respiratory disorders, and clinical scientists, physicians, drug companies, and healthcare services and workers.